Radwan Sohab S, Schwartz Owen G
Department of Internal Medicine, MedStar Washington Hospital Center, USA.
Case Rep Cardiol. 2019 Apr 8;2019:6240605. doi: 10.1155/2019/6240605. eCollection 2019.
Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals.
雷加曲班是一种选择性腺苷2A（A2a）受体激动剂，用于心脏负荷试验以评估缺血性心脏病，在现代已基本取代了腺苷。由于腺苷受体参与包括大脑皮层、海马体等在内的整个中枢神经系统（CNS）中神经元之间的突触传递，雷加曲班可降低易感个体的癫痫发作阈值。致痫活性是使用雷加曲班时一种罕见但可能严重的不良反应，因此，在筛查高危患者以及评估易感个体中研究冠状动脉疾病（CAD）的替代方法时，需要提高认识。
